A prominent advocacy group has raised formal objections regarding the composition of a government-appointed committee tasked with evaluating pharmaceutical marketing practices. The Working Group on Access to Medicines and Treatments has submitted a representation to the Department of Pharmaceuticals, calling for the removal of Dr. Naresh Trehan, the chairman and managing director of the Medanta Group, from the panel. The committee was established following directives from the Supreme Court to review the regulatory framework and provide recommendations concerning the voluntary Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024.
The advocacy group argues that Dr. Trehan’s professional and financial associations with the Medanta hospital chain create a significant conflict of interest. According to the group, the panel's ability to remain independent and impartial is essential for ensuring that its eventual recommendations are rooted strictly in public health priorities and the promotion of ethical industry standards. They contend that allowing individuals with potential financial stakes in the healthcare sector to oversee regulatory reforms may undermine the credibility of the committee's work.
In its communication to the government, the group referenced a 2018 report by the National Pharmaceutical Pricing Authority (NPPA). That report, which investigated billing practices at four different hospitals, allegedly identified instances of overcharging at Medicity-Medanta. Furthermore, the group pointed toward ongoing Supreme Court proceedings and separate assessments conducted by state-level drug regulatory authorities in Maharashtra, Uttar Pradesh, and Karnataka. These bodies have previously scrutinized the high markups applied to hospital tariffs, a factor the advocacy group believes is directly relevant to the committee’s mandate.
The group emphasized that their objection is not a blanket opposition to stakeholder consultation. Instead, they clarified that their request is specifically focused on maintaining the integrity of the committee’s composition. They warned that if the panel is not reconstituted with members who are free from such conflicts, the fundamental purpose of the Supreme Court’s original directive—to ensure transparent and public-interest-led reform—could be defeated.
The committee in question is currently charged with examining the broader regulatory landscape for pharmaceutical marketing. The primary objective is to make recommendations regarding the UCPMP, which serves as the current voluntary guideline for how pharmaceutical companies interact with healthcare providers. The advocacy group maintains that for these recommendations to be effective and widely accepted, the process must be perceived as entirely impartial by the public.
By requesting the Department of Pharmaceuticals to appoint a member without these alleged conflicts, the group is seeking to ensure that the committee’s deliberations remain focused on increasing access to affordable healthcare. The representation concludes by reiterating the necessity for the government to take corrective action to safeguard the impartiality of the review process. As of now, the Department of Pharmaceuticals has received the representation, though there has been no official statement regarding any changes to the committee's membership.
The outcome of this challenge could set a precedent for how the government constitutes expert panels that involve industry leaders. With the Supreme Court having initiated the review, the pressure remains on the authorities to demonstrate that the regulatory framework for pharmaceutical marketing is developed through a process that is both transparent and robust enough to withstand public scrutiny. The advocacy group’s intervention highlights the ongoing tension between industry representation and the need for independent oversight in the Indian healthcare regulatory environment.
Comments